July 26, 2018HaematologicaOpen Access

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

View Full Paper

Ask AI

Bookmark

Why the study?

What are the cardiovascular adverse events associated with modern anti-myeloma therapy, particularly carfilzomib, in patients with multiple myeloma?

Population

Patients with multiple myeloma

Design

Review

Authors

SBSara BringhenAzienda Ospedaliera Citta' della Salute e della Scienza di Torino AMAlberto MilanCardio-Oncology CFClaudio FerriPreventive Cardiology

Discussion

Member takes

Implication

Raises clinician awareness of carfilzomib CV risks in myeloma; leaves open consensus recommendations for management.

Structured PICO

What are the cardiovascular adverse events associated with modern anti-myeloma therapy, particularly carfilzomib, in patients with multiple myeloma?

Population

Patients with multiple myeloma

Intervention

Modern anti-myeloma therapy (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors), with a focus on carfilzomib

Outcome

Cardiovascular adverse eventssafety

This review highlights the importance of recognizing and managing cardiovascular adverse events associated with modern multiple myeloma therapies, particularly carfilzomib, to balance efficacy and toxicity.

Cite This Study

Bringhen et al. (2018) studied this question.

synapsesocial.com/papers/6a8371fba7c4deaff829ac91 https://doi.org/10.3324/haematol.2018.191288

Topics

Cardio-oncology Cardiovascular prevention

View Full Paper

Ask AI

Bookmark

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider